<DOC>
	<DOCNO>NCT00533585</DOCNO>
	<brief_summary>The goal study find high tolerable dose BAY 43-9006 ( sorafenib ) bevacizumab give paclitaxel carboplatin patient non-small cell lung cancer ( NSCLC ) . The safety effectiveness drug combination also study .</brief_summary>
	<brief_title>BAY 43-9006 Previously Untreated Patients With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Sorafenib design stop growth cell cause genetic change often associated cancer . Paclitaxel design work block mechanism cell division cancer cell , may cause die . Carboplatin design work interfere growth cancer cell stop cell division . Bevacizumab design prevent slow growth cancer cell block effect blood-vessel stimulating agent play important role growth normal abnormal blood vessel . If find eligible take part study , receive 4 different drug study . This study follow 3-week schedule know study `` cycle . '' In first part study , researcher try find high dose study drug safely give together . The first group 6 participant receive low dos sorafenib bevacizumab . The dos paclitaxel carboplatin stay 6 cycle study participant complete 6 cycle . If first 6 participant intolerable side effect , next group patient get high dos bevacizumab . The dos sorafenib increase least participant unacceptable side effect . The dose get increase study , bad side effect , dose sorafenib , bevacizumab , paclitaxel , carboplatin may lower future visit . On Day 1 cycle , give bevacizumab , paclitaxel , carboplatin vein infusion . Paclitaxel infuse 3 hour , follow carboplatin 30 minute , follow bevacizumab 90 minute first 2 cycle . Your bevacizumab infusion may give short time period later cycle . You stay clinic least 30 minute bevacizumab infusion cycle 1 2 . You take sorafenib mouth twice day , morning 11:00 evening 11:00 p.m. Sorafenib take 1 cup water empty stomach ( either 1 hour meal 2 hour meal ) moderate fat diet ( 30 % calorie fat ) . Sorafenib must swallow whole without chew . On Day 1 Cycles 1 2 , complete medical history record , physical exam include measurement vital sign weight . You ask question find disease progress disease affect quality life . You ask side effect may experience . If possible , change medication Cycle 1 Day 1 procedure complete Cycle 2 Day 3 . Blood ( 5 teaspoon ) urine collect routine test . You receive infusion paclitaxel , carboplatin , bevacizumab vein . On Cycle 1 Day 2 , blood ( 1 tablespoon ) drawn routine test . On Cycle 1 Day 3 , blood ( 1 tablespoon ) collect routine test . After blood sample collect , give morning dose sorafenib . You give sorafenib take home night . On Cycle 2 Day 2 , blood ( 1 tablespoon ) drawn routine test . Once blood sample collect , morning dose sorafenib give clinic . You give sorafenib take home night . On Cycle 2 Day 3 , blood ( 1 tablespoon ) drawn routine test . Once blood sample collect , morning dose sorafenib give clinic . Before leave clinic , give enough sorafenib tablet last next cycle visit . On Cycles 1-2 Days 8 15 , complete medical history record , physical exam include measurement vital sign weight . You performance status evaluation . You ask side effect may experience . Blood ( 5 teaspoon ) urine collect routine test . On Day 1 Cycle 3 remain cycle , return study medication and/or empty bottle . Your complete medical history record , physical exam include measurement vital sign weight . You ask question determine disease progressing , disease affect quality life . You ask side effect may experience . Blood ( 5 teaspoon ) urine collect routine test . You receive infusion paclitaxel , carboplatin , bevacizumab . You stay clinic least 30 minute bevacizumab infusion . Before leave clinic , give enough sorafenib last next cycle . On Days 8 15 Cycle 3 remain cycle , blood ( 5 teaspoon ) urine collect routine test . On Day 1 odd-numbered cycle ( start Cycle 3 , 5 , 7 , 9 ... ) , CT scan , MRI scan , and/or x-rays check status disease . Modified Dose Levels 4 5 : To find interrupted dose sorafenib result few less severe side effect , 2 additional dose level , dose sorafenib change ( modify ) , perform . For Modified Dose Level 4 , sorafenib interrupt 2 day every 4-5 day . For Modified Dose Level 5 , sorafenib interrupt 1 week 2 week continuous therapy . For 2 additional dose level , sorafenib dose schedule change . There 6 patient enrol dose level . Participants Dose Level 4 may continue treatment 4 6 cycle . This do accurately evaluate dose level . Researchers evaluate side effect related new dose schedule sorafenib . After 6 patient enrol Dose level 4 , 6 additional patient enrol Dose Level 5 . If intolerable side effect see Dose Level 5 , 6 additional patient enrol dose level . This do additional PK test do . For Modified Dose Level 4 5 , `` Day 1 Cycle 1 2 , give bevacizumab , paclitaxel , carboplatin vein infusion . Paclitaxel infuse 3 hour , follow carboplatin 30 minute , follow bevacizumab 90 minute first 2 cycle . Your bevacizumab infusion may give short time period later cycle . You stay clinic least 30 minute bevacizumab infusion cycle 1 2. `` Modified Dose level 4 : For Modified Dose level 4 , Day 3 Day 19 Cycle 1 , receive sorafenib mouth morning , morning PK test collect ( Day 3 ) . Participants take even dose sorafenib . After , participant take sorafenib twice day 5 day 2 day . This continue Day 19 outpatient basis . On Day 2 Day 19 Cycle 2 , receive sorafenib mouth morning , morning PK test collect Day 2 ( Cycle 2 ) . Participants take even dose sorafenib . After , participant take sorafenib twice day 5 day 2 day . This continue Day 19 outpatient basis . The modified dose level 4 5 patient take sorafenib Days 1 , 2 , 6 , 7 , 13 , 14 , 20 21 Cycle 1 . Modified Dose level 5 : For Modified Dose Level 5 , Day 3 Day 15 Cycle 1 , receive sorafenib mouth morning , morning PK test collect ( Day 3 ) . Participants take even dose sorafenib . After , participant take sorafenib twice day 14 day Day 15 outpatient basis . Participants take sorafenib Days 1 , 2 Days 16-21 . On Day 2 Day 15 Cycle 2 , receive sorafenib mouth morning , morning PK test collect ( Day 2 Cycle 2 ) . Participants take even dose sorafenib . After , participant take sorafenib twice day 14 day Day 15 outpatient basis.Participants take sorafenib Days 1 , 2 Days 16-21 . You may stay study long disease get bad , intolerable side effect develop . Once study , end-of-study visit 21-35 day last dose study drug . You need return unused study medication and/or empty bottle . You physical exam , include measurement vital sign , height , weight . You performance status evaluation ECG . You ask side effect may experience . CT scan , MRIs , and/or x-ray take check status disease . Blood ( 5 teaspoon ) urine collect routine blood test . Women able child must negative blood ( 1-2 teaspoon ) pregnancy test . This investigational study . Sorafenib , paclitaxel , carboplatin , bevacizumab FDA approve commercially available . The combination 4 drug FDA approve , authorize use research . Up 60 patient take part multicenter study . Up 30 patient enrol M.D . Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . 2 . Patients must Stage IIIB ( malignant pleural effusion ) Stage IV histological cytological confirmation nonsmall cell carcinoma ( exclude squamous ) . 3 . Age &gt; /= 18 year old 4 . Patients must least 1 measurable lesion . Lesions must evaluate computed tomography ( CT ) scan magnetic resonance imagining ( MRI ) 5 . Eastern Cooperative Oncology ( ECOG ) Performance Status 0 1 6 . Controlled blood pressure ( define systolic BP &lt; /= 150mmHg diastolic &lt; /= 90 mmHg ) 7 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior start first dose : Hemoglobin &gt; /= 9.0 g/dL ; White blood cell ( WBC ) count &gt; /= 2,500/mm3 , Absolute neutrophil count ( ANC ) &gt; /= 1,500/mm3 , Platelet count &gt; /= 100,000/mm3 , Total bilirubin &lt; /= 1.5 time upper limit normal ( ULN ) , ALT AST &lt; /= 2.5 x ULN ( &lt; /=5 x ULN patient liver involvement ) , international normalize ratio ( INR ) &lt; /= 1.5 activate partial thromboplastin time ( aPTT ) within normal limit . 8 . Inclusion Criteria # 7 : Serum creatinine &lt; /= ULN creatinine clearance ( CrCl ) &gt; /= 45 mL/min ( CrCl = Wt ( kg ) x ( 140 age ) /72 x Cr level , female x 0.85 ) patient creatinine level institutional normal . Urinalysis ( UA ) must show less 1+ protein urine , patient require repeat UA . If repeat UA show 1+ protein , 24 hour collection require must show total protein &lt; /= 1000 mg/24 hour eligible 9 . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . 10 . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation , include 30 day period last study drug dosing . The investigator advise patient consider adequate contraception . 1 . Patients squamous histology . 2 . Cardiac disease : Congestive heart failure ( CHF ) &gt; Class II New York Heart Association ( NYHA ) ; active coronary artery disease ( myocardial infarction ) [ MI ] 6 month prior study entry allow ) ; serious cardiac ventricular arrhythmia require antiarrhythmic therapy ( betablockers digoxin permit ) 3 . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management 4 . Human Immunodeficiency Virus ( HIV ) infection chronic hepatitis B C 5 . Active clinically serious infection ( &gt; Grade 2 NCICTC Version 3.0 ) 6 . History brain metastasis . Patients history brain metastasis eligible long metastasis treat either stereotactic whole brain radiation neurosurgery , patient require ongoing treatment dexamethasone patient 's radiographic image stable &gt; /= 4 week start treatment . Time brain metastasis treatment first study treatment must meet following criterion : Stereotactic whole brain radiation &gt; /= 4 week first study treatment , Neurosurgery &gt; /= 24 week first study treatment , continue exclusion # 7 7 . Continued exclusion criterion # 6 : Brain biopsy &gt; /= 12 week first study treatment . 8 . Uncontrolled seizure disorder . Use cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine phenobarbital ) allow 9 . Thrombotic embolic event cerebrovascular accident , transient ischemic attack , deep vein thrombosis pulmonary embolism 10 . Organ allograft 11 . Evidence history bleed diathesis coagulopathy 12 . History of/or current evidence hemoptysis ( bright red blood 1/2 teaspoon ) 13 . Peripheral neuropathy &gt; /= Grade 2 14 . Anticancer chemotherapy immunotherapy : Anticancer therapy define agent combination agent clinically proven anticancer activity administer route purpose affect cancer , either directly indirectly , include palliative therapeutic endpoint ( except patient receive adjuvant chemotherapy &gt; 52 week Cycle 1 Day 1 ) 15 . Radiotherapy target lesion within 3 week start first dose . Toxicities radiotherapy must resolve prior start first dose . 16 . No major surgery , open biopsy significant traumatic injury within 4 week start first dose 17 . Serious , nonhealing wound , ulcer , bone fracture 18 . Granulocyte growth factor ( GCSF ) , within 3 week study entry . 19 . Patients take chronic erythropoietin permit provide dose adjustment make within 2 month prior start first dose 20 . Pregnant breast feeding patient 21 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 22 . Known suspect allergy recombinant human antibody , compound similar chemical biologic composition sorafenib drug study 23 . Any condition unstable could jeopardize safety compliance patient study 24 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical cancer situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis , T1 ) cancer curatively treat &gt; 3 year prior study entry 25 . Any condition impair patient 's ability swallow pill whole 26 . Any malabsorption condition 27 . Therapeutic anticoagulation warfarin , heparin , heparinoids 28 . Patients takin phenytoin , carbamazepine , Phenobarbital 29 . Patients take rifampin , St. John 's Wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>malignant pleural effusion</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>BAY 43-9006</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
</DOC>